Despite Cigna and Humana ditching their pursuits to combine in December, one industry expert believes there's still a chance after Cigna announced its plan to sell its Medicare Advantage business to Health Care Service Corp.
AI, health equity and merger and acquisition activity are among the trends to watch in 2024, according to a recent report from Deloitte.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Hospitals weathered one of their most challenging years in 2022, with median operating margins staying in the red throughout most of the year. Those money problems proved to be a major factor shaping last year’s M&A transactions — financial pressures influenced 28% of hospital M&A deals last year, up from 15% in 2022, a new report showed.
Experts have predicted that 2024 will be an eventful year for hospital M&A activity. As the industry prepares for another big year, there are a few things that health system leaders involved in these deals should keep in mind to make the process as smooth as possible, according to DexCare CEO Derek Streat.
Molina Healthcare's purchase price of Bright Health Group's Medicare Advantage business has dropped from $600 million to $500 million. This will make it increasingly difficult for Bright Health to pay off its debts, one expert said.
Integrations are incredibly destabilizing and stressful for impacted employees, as well as for those who “survive.” Organizations that are worth acquiring are successful and attractive because they are comprised of smart, talented people who have created that success.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
With Cigna mostly focused on the commercial market and Humana mostly focused on the Medicare Advantage market, the rumored combination rumors check out, according to one industry expert.
The Orchard Therapeutics acquisition comes as the biotech’s gene therapy for metachromatic leukodystrophy approaches a March 2024 FDA decision. The ex vivo gene therapy is already commercialized in Europe, marketed as Libmeldy.
Intercept Pharmaceuticals’ acquisition by Alfasigma comes three months after the FDA again rejected the biotech’s drug as a treatment for the fatty liver disease NASH. But Intercept still has rare liver disease assets, and Italy-based Alfasigma says acquiring the company will help it expand in gastroenterology and hepatology.
The Federal Trade Commission only gets notified when a merger/acquisition deal value is above $100-$110 million, so smaller deals nonetheless lead to a slow consolidation of the market. In conference remarks, FTC Chair Lina Khan outlined the ways in which the agency is trying to counter this phenomenon.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Peanut allergy therapy Palforzia, which Nestlé acquired in a multi-billion dollar deal, has been sold to allergy product company Stallergenes Greer. Palforzia was the first FDA-approved drug for peanut allergy, but its sales were hampered by the Covid-19 pandemic.
Healthcare M&A deals are expected to pick up over the next few months, and one expert is predicting that the biopharma sector in particular will see especially robust activity. M&A lawyer Matt Gardella said there are three sets of market circumstances that will lead to an influx of biopharma deals: a looming patent cliff, shrinking valuations and a weak IPO market.
M&A activity in the healthcare sector continued to decline in the second quarter of 2023, with the number of deals reaching its lowest point in three years. However, a new report predicted that M&A activity could increase in the second half of this year due to healthcare companies’ continually shrinking valuations and their divestitures of non-core assets.
M&A activity among hospitals and health systems increased in Q2 of 2023 — there were 20 deals in Q2 compared to 15 deals in Q1, according to a new report. This surge brought Q2’s M&A activity levels in line with those observed before the pandemic. Q2’s 20 deal marks the highest number of announced transactions for hospitals and health systems since Q1 of 2020.
CorEvitas brings Thermo Fisher Scientific registries that gather data about how approved therapies are working in the real world. The acquisition will complement PPD, the contract research organization that Thermo Fisher purchased in 2021.